

Walter H Moos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1074291/publications.pdf>

Version: 2024-02-01

90
papers

4,910
citations

196777

29
h-index

104191

69
g-index

96
all docs

96
docs citations

96
times ranked

4708
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury. <i>Biochemical Pharmacology</i> , 2022, 203, 115168.	2.0	10
2	Are in-person scientific conferences dead or alive?. <i>FASEB BioAdvances</i> , 2021, 3, 420-427.	1.3	12
3	Pathogenic mitochondrial dysfunction and metabolic abnormalities. <i>Biochemical Pharmacology</i> , 2021, 193, 114809.	2.0	21
4	Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. <i>BioResearch Open Access</i> , 2020, 9, 94-105.	2.6	17
5	Epigenetic treatment of dermatologic disorders. <i>Drug Development Research</i> , 2019, 80, 702-713.	1.4	1
6	Building on Success: A Bright Future for Peptide Therapeutics. <i>Protein and Peptide Letters</i> , 2019, 25, 1044-1050.	0.4	23
7	Peptides 2020: A Clear Therapeutic Vision. <i>Protein and Peptide Letters</i> , 2019, 25, 1042-1043.	0.4	3
8	A New Approach to Treating Neurodegenerative Otologic Disorders. <i>BioResearch Open Access</i> , 2018, 7, 107-115.	2.6	10
9	Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. <i>BioResearch Open Access</i> , 2017, 6, 123-132.	2.6	45
10	Epigenetic Treatment of Persistent Viral Infections. <i>Drug Development Research</i> , 2017, 78, 24-36.	1.4	17
11	Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future. <i>BioResearch Open Access</i> , 2017, 6, 169-181.	2.6	13
12	Chemical development. , 2017, , 459-466.		0
13	FDA path and process. , 2017, , 467-485.		0
14	Graduate and postgraduate education at a crossroads. , 2017, , 103-128.		1
15	Drug discovery. , 2017, , 281-420.		1
16	Drug discovery. , 2017, , 183-279.		1
17	Research and discovery. , 2017, , 421-436.		0
18	Doctoral and professional programs. , 2017, , 141-169.		0

#	ARTICLE	IF	CITATIONS
19	Backgrounder. , 2017, , 3-29.		0
20	Master's degree programs. , 2017, , 129-139.		3
21	Turning a potent agent into a registered product. , 2017, , 439-447.		0
22	Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Drug Development Research, 2016, 77, 109-123.	1.4	49
23	Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. Drug Development Research, 2016, 77, 53-72.	1.4	30
24	Microbiota and Neurological Disorders: A Gut Feeling. BioResearch Open Access, 2016, 5, 137-145.	2.6	108
25	Mitochondrial Drugs Come of Age. Drug Development Research, 2015, 76, 57-60.	1.4	9
26	Bioprotective Carnitinoids: Lipoic Acid, Butyrate, and Mitochondria Targeting to Treat Radiation Injury: Mitochondrial Drugs Come of Age. Drug Development Research, 2015, 76, 167-175.	1.4	13
27	A tribute to David Triggle. Biochemical Pharmacology, 2015, 98, 360-362.	2.0	4
28	Radiation Drugs "Still a Hot Topic. Drug Development Research, 2014, 75, 1-2.	1.4	1
29	Biomarkers "An Essential Tie That Binds the Future of Drugs and Diagnostics. Drug Development Research, 2013, 74, 63-64.	1.4	7
30	A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. PLoS ONE, 2013, 8, e60579.	1.1	223
31	Radiation Drugs-A Hot Topic. Drug Development Research, 2012, 73, 229-231.	1.4	5
32	Evaluation of the pK_a values and ionization sequence of bumetanide using 1H and ^{13}C NMR and UV spectroscopy. Drug Development Research, 2011, 72, 416-426.	1.4	4
33	Review of the effects of $^{17}\beta$ -estradiol in humans: a less feminizing estrogen with neuroprotective potential. Drug Development Research, 2009, 70, 1-21.	1.4	26
34	Nonprofit organizations and pharmaceutical research and development. Drug Development Research, 2009, 70, 461-471.	1.4	9
35	Bright lights, clearly visible in the healthcare R&D tunnel, could burn out for lack of funds. Drug Development Research, 2009, 70, 457-460.	1.4	1
36	Combinatorial chemistry: oh what a decade or two can do. Molecular Diversity, 2009, 13, 241-245.	2.1	36

#	ARTICLE	IF	CITATIONS
37	17 β -estradiol: a less-feminizing estrogen. Drug Development Research, 2008, 69, 177-184.	1.4	8
38	Nanobiotechnology: it's a small world after all. Drug Development Research, 2006, 67, 1-3.	1.4	18
39	Development of 17 β -Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study. Annals of the New York Academy of Sciences, 2005, 1052, 116-135.	1.8	81
40	Estrogens and Neuroprotection: desperate housewives, lost, and survivor. Drug Development Research, 2005, 66, 51-52.	1.4	2
41	Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. Drug Development Research, 2005, 66, 53-77.	1.4	6
42	Ethical Issues in the Biotechnology and Pharmaceutical Industries. Drug Development Research, 2004, 63, 89-92.	1.4	3
43	Efficient Syntheses of Benzothiazepines as Antagonists for the Mitochondrial Sodium ⁺ Calcium Exchanger: A Potential Therapeutics for Type II Diabetes. Journal of Organic Chemistry, 2003, 68, 92-103.	1.7	48
44	The Biotechnology industry in a period of opportunity and uncertainty. Drug Development Research, 2002, 57, 45-50.	1.4	5
45	Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Molecular and Cellular Proteomics, 2002, 1, 763-780.	2.5	73
46	Cell death as a life force. Drug Development Research, 2001, 52, 505-507.	1.4	0
47	Pharmacogenomics 2000. , 2000, 49, 1-3.		2
48	Characterization of Novel Antimicrobial Peptoids. Antimicrobial Agents and Chemotherapy, 1999, 43, 1429-1434.	1.4	116
49	Combinatorial discovery process yields antimicrobial peptoids. Bioorganic and Medicinal Chemistry, 1999, 7, 1781-1785.	1.4	61
50	Mitochondria: The biochemical power plants of cells. , 1999, 46, 1-1.		2
51	Introduction to mitochondrial function and genomics. , 1999, 46, 2-13.		10
52	Foreword. , 1998, 61, 5-6.		0
53	Design and Synthesis of m1-Selective Muscarinic Agonists: (R)-(α)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one,O-(3-(3-Methoxyphenyl)-2-propynyl)- oxime Maleate (CI-1017), a Functionally m1-Selective Muscarinic Agonist. Journal of Medicinal Chemistry, 1998, 41, 2524-2536.	2.9	29
54	From genes to drugs: Better, faster, cheaper. , 1997, 41, 111-111.		4

#	ARTICLE	IF	CITATIONS
55	Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies. <i>Drug Development Research</i> , 1995, 34, 243-259.	1.4	39
56	Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers. <i>Drug Development Research</i> , 1995, 35, 20-32.	1.4	383
57	Molecular diversity comes of age !. <i>Molecular Diversity</i> , 1995, 1, 1-3.	2.1	3
58	Measuring Diversity: Experimental Design of Combinatorial Libraries for Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1431-1436.	2.9	375
59	Post-modification of peptoid side chains: [3+2] cycloaddition of nitrile oxides with alkenes and alkynes on the solid-phase. <i>Tetrahedron Letters</i> , 1994, 35, 5825-5828.	0.7	65
60	Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994, 4, 2657-2662.	1.0	289
61	Recent advances in the generation of chemical diversity libraries. <i>Drug Development Research</i> , 1994, 33, 174-188.	1.4	58
62	Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2678-2685.	2.9	378
63	Using Peptoid Libraries [Oligo N-Substituted Glycines] for Drug Discovery. <i>Techniques in Protein Chemistry</i> , 1994, 5, 533-539.	0.3	13
64	Pharmaceutical applications of biotechnology: Promise and reality. Editorial overview. <i>Current Opinion in Biotechnology</i> , 1993, 4, 711-713.	3.3	6
65	The generation of molecular diversity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 387-396.	1.0	116
66	Chapter 33. Recent Advances in the Generation of Molecular Diversity. <i>Annual Reports in Medicinal Chemistry</i> , 1993, , 315-324.	0.5	76
67	Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. <i>Journal of the American Chemical Society</i> , 1992, 114, 10646-10647.	6.6	1,139
68	Cholinomimetics and Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1992, 2, 777-780.	1.0	21
69	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1992, 2, 803-808.	1.0	22
70	Acetylcholine releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1992, 2, 855-860.	1.0	1
71	Cholinergic Agents: Effect of Methyl Substitution in a Series of Arecoline Derivatives on Binding to Muscarinic Acetylcholine Receptors. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 1015-1019.	1.6	12
72	A silica gel plate-based qualitative assay for acetylcholinesterase activity: A mass method to screen for potential inhibitors. <i>Analytical Biochemistry</i> , 1991, 196, 439-442.	1.1	28

#	ARTICLE	IF	CITATIONS
73	Cholinergic agents: Deficits in rat hippocampal choline acetyltransferase activity and spatial working memory induced by intracerebroventricular administration of stoichiometrically prepared 1-ethyl-1-(2-hydroxyethyl) aziridinium ion (AF64A). <i>Drug Development Research</i> , 1991, 23, 253-260.	1.4	0
74	Conformation of three tetrahydropyridinyl oxime cognition activators. <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, 21, 419-429.	0.3	2
75	Novel Muscarinic Agonists for the Treatment of Alzheimer's Disease. , 1991, , 347-353.		4
76	Benzo-fused bicyclic imides. <i>Journal of Organic Chemistry</i> , 1990, 55, 560-564.	1.7	30
77	The Muscarinic Receptors. The Receptors. Joan Heller Brown. <i>Quarterly Review of Biology</i> , 1990, 65, 381-381.	0.0	0
78	Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide. <i>Psychopharmacology</i> , 1989, 99, 103-108.	1.5	42
79	A SIMPLIFIED PROCEDURE FOR PREPARING THE CHOLINERGIC NEUROTOXIN 1-ETHYL-1-(2-HYDROXYETHYL)AZIRIDINIUM ION (AF64A). <i>Organic Preparations and Procedures International</i> , 1989, 21, 315-319.	0.6	5
80	Adenosine Receptor Agonists. X-Ray Crystal Structure of Neca 1-(6-Amino-9H-Purin-9-yl)-1-Deoxy-N-Ethyl- β -D-Ribofuranuronamide. <i>Nucleosides & Nucleotides</i> , 1989, 8, 449-461.	0.5	7
81	Cognition activators. <i>Medicinal Research Reviews</i> , 1988, 8, 353-391.	5.0	100
82	Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. <i>Journal of Medicinal Chemistry</i> , 1987, 30, 1963-1972.	2.9	89
83	N ⁶ -(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. <i>Journal of Medicinal Chemistry</i> , 1987, 30, 1709-1711.	2.9	54
84	Drug development for senile cognitive decline. <i>Journal of Medicinal Chemistry</i> , 1986, 29, 1125-1130.	2.9	45
85	Ribose-modified adenosine analogs as adenosine receptor agonists. <i>Journal of Medicinal Chemistry</i> , 1986, 29, 346-353.	2.9	53
86	Chapter 4. Cognitive Disorders. <i>Annual Reports in Medicinal Chemistry</i> , 1986, , 31-40.	0.5	1
87	The reaction of pyridazinones with nucleophiles. An unusual reaction with cyanide. <i>Journal of Heterocyclic Chemistry</i> , 1986, 23, 1515-1517.	1.4	7
88	Studies on the Preparation, Isolation, and Reactions of Adenosine Schiff Bases. <i>Nucleosides & Nucleotides</i> , 1986, 5, 201-212.	0.5	0
89	N ⁶ -Cycloalkyladenosines. Potent, A ₁ -selective adenosine agonists. <i>Journal of Medicinal Chemistry</i> , 1985, 28, 1383-1384.	2.9	104
90	Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. <i>Journal of Medicinal Chemistry</i> , 1984, 27, 1099-1101.	2.9	159